KA (Kineta Inc) שיעור רווח גולמי

Kineta, Inc. is developing cancer immunotherapy via the VISTA platform to stimulate innate immunity. The final gross margin on the GURU.Markets terminal line chart confirms this trajectory, where the level 0.00 represents the current value. However, the outsourcing of antibody production and a management crisis, which led to the freezing of tests to save costs, create uncertainty for future performance.
פילוחים אנליטיים ודוחות נתונים של חברת Kineta Bio (KA)

The virtual model of biotech Kineta, Inc. (KA) minimizes internal costs by outsourcing clinical trials to external contractors. By analyzing historical gross margins, an investor can identify the portion of revenue remaining after paying these production expenses. This metric measures operational production efficiency, where steady growth confirms cost control and protects capital from the risks of deep asset drawdowns.